Table 3 Summary of back-transformed LS means PCV2 copies/5 µL in serum (viremia) or feces (fecal shedding) by qPCR by treatment and study day for study A
Treatment Group (T) and description | Endpoint | n | Day of study | ||||||
|---|---|---|---|---|---|---|---|---|---|
|  | Vaccine | Challenge | − 1 | 21 | 28 | 35 | 42 | ||
T01 | Saline | PCV2a | Viremia | 10 | 0 | 0 | 1.09E + 04 | 2.30E + 04 | 1.91E + 03 |
T02 | cPCV2a | PCV2a | 10 | 0 | 0 | 43 | 2 | 2 | |
T03 | Saline | PCV2b | 9 | 0 | 0 | 3.04E + 04 | 2.81E + 05 | 5.18E + 03 | |
T04 | cPCV2a | PCV2b | 10 | 0 | 0 | 1.87E + 03 | 22 | 2 | |
T01 | Saline | PCV2a | Fecal Shedding | 10 | 0 | 0 | 1.84E + 02 | 4.13E + 03 | 2.35E + 04 |
T02 | cPCV2a | PCV2a | 10 | 0 | 0 | 0 | 16 | 2 | |
T03 | Saline | PCV2b | 9 | 0 | 0 | 2.57E + 02 | 2.48E + 04 | 1.07E + 05 | |
T04 | cPCV2a | PCV2b | 10 | 0 | 0 | 7 | 7 | 0 | |